一种LDL吸附剂载体-聚丙烯酰胺微球的合成及应用

研究用于低密度脂蛋白 (L DL)吸附的聚丙烯酰胺微球载体的合成工艺、结构特性及吸附 L DL 的性能 ,为进一步研发 L DL 吸附剂载体提供实验依据。采用反相悬浮聚合法按一定的配方合成聚丙烯酰胺微球载体 ,通过扫描电镜、图像分析仪、X光小角散射等手段对其结构特性 (粒径、孔径等 )进行表征 ;同时在微球上固定丝氨酰 -天冬氨酰 -谷氨酸 (SDE)三肽配体制成 L DL 吸附剂 ,通过体外静态吸附对其吸附性能进行了初步研究。结果表明微球粒径为 14 2 .1μm,孔径为 119.8nm,符合作为 L DL 吸附载体的需要 ;在交联剂与单体总量一定的条件下 ,微球孔径随着交联剂用量的增加而减小 ;合成的聚丙烯酰胺微球对 L DL 的非特异性吸附很小 ,而在其上偶联配体制成吸附剂后 ,又表现出对 L DL 的特异性吸附。本实验合成的聚丙烯酰胺微球是一种有效的 L DL 吸附剂载体。     

Seven DNA polymorphisms in the LDL receptor gene: application to the study of familial hypercholesterolemia in Spain

We have performed restriction fragment length polymorphism (RFLP) analysis at the low density lipoprotein receptor (LDLR) locus in order to investigate the molecular genetics of familial hypercholesterolemia (FH) in Spain. Firstly, a sample of 50 unrelated patients with a clinical diagnosis of FH was screened for the presence of major rearrangements at this locus by Southern blot analysis of Bgt II digested genomic DNA. Four different mutations were detected, accounting for 8% of the mutant alleles in the Spanish FH sample. Then, we determined the relative allele frequency and estimated linkage disequilibrium between seven RFLPs of the LDLR gene in the remaining 46 FH patients and in 61 normolipidemic controls. Hindi, Avail, Pvu II, Msp I, and Nco I are the most polymorphic sites with individual PIC values higher than 0.28, whereas the Taq I and Stu I sites display low levels of polymorphism. The usefulness of the seven RFLPs to confirm a clinical diagnosis of FH was investigated in 15 FH-families, consisting of 118 individuals, in whom the presence of Familial Defective Apolipoprotein B-100 (FDB) due to the apoB₃₅₀₀ mutation was excluded. Independent haplotypes were constructed for 71 chromosomes: 15 FH and 56 control haplotypes. A total of 14 different haplotypes was found. In 12 families, clinical diagnosis of FH was confirmed by cosegregation analysis, which makes these RFLPs useful for studying the inheritance of the LDLR gene in 80% of Spanish families with FH. Comparison of haplotypes found in the Spanish sample with those found in Swiss and Norwegians suggests heterogeneity of haplotypes among European populations.     

胎牛主动脉内皮细胞LDL受体分析

培养的胎牛主动脉内皮细胞具有可饱和性、高亲和性和配体持异性的LDL受体。该受体最大结合容量(Bmax)为378ng/mg细胞蛋白,平衡亲和常数(kd)为13μg/ml据估计,每个细胞表面的受体数目为8～9万。我们初步发现亚融合和融合但失去“接触抑制”特点的FBAE的LDL受体活性无明显差异。     

Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.

BACKGROUND: Sevelamer hydrochloride was recently proposed as a phosphate binder to prevent hypercalcaemia in place of calcium alkaline salts in dialysis patients. So far, it has been evaluated only in patients receiving calcitriol, without comparison with CaCO(3) alone, although the latter was found to be as effective as the combination of calcitriol and Al(OH)(3) in suppressing parathyroid hormone (PTH) without inducing hypercalcaemia and to have a better lowering effect on serum phosphate. Moreover, this bile salt binder may decrease serum 25-OH vitamin D. Therefore, we compared for 5 months two strategies for controlling moderate hyperparathyroidism: CaCO(3) alone vs sevelamer in conjunction with measures to increase calcium balance. METHODS: Forty-two patients were randomized: 21 continued their treatment with 4.8 g/day CaCO(3) and 21 were switched to sevelamer (initial dose: 2.4 g/day, increased to 4.4 g/day). Each month, when serum-corrected calcium decreased below 2.30 mmol/l, dialysate calcium was increased or alphacalcidol was given at each dialysis session, according to serum PO(4) levels. The following parameters were monitored: serum Ca, PO(4), bicarbonate and protein, weekly; and serum PTH, 25-OH vitamin D and total, LDL and HDL cholesterol monthly. RESULTS: Except for higher serum phosphate at month 1, lower serum bicarbonate at month 2 and lower LDL cholesterol at month 5 in the sevelamer group, no difference was found between the two groups. Compared with baseline levels, PTH increased and 25-OH vitamin D decreased significantly in both groups, these two parameters being inversely correlated. CONCLUSIONS: Given comparable control of plasma calcium, phosphate and 25-OH vitamin D, PTH control is comparable in both strategies. Sevelamer does not induce greater vitamin D depletion than CaCO(3). The transient decrease of serum bicarbonate after discontinuation of CaCO(3) in the sevelamer group suggests a less optimal prevention of acidosis. The sevelamer-induced decrease in LDL cholesterol gives this drug a potential advantage in cardiovascular prevention.     

冠心病患者低密度脂蛋白中甘油三酯异常特征

本文检测了不同年龄健康人和冠心病（ＣＨＤ）患者血脂及各脂蛋白组分中甘油三脂（ＴＧ）、胆固醇（ＣＨ）水平，结果示总ＴＧ、低密度脂蛋白（ＬＤＬ）－ＴＧ、ＬＤＬ－ＴＧ／ＬＤＬ－ＣＨ比值升高，为ＣＨＤ最为显著的脂质异常特征。分析了ＣＨＤ患者ＬＤＬ脂质构成异常的特征及成因，认为高ＬＤＬ－ＴＧ／ＬＤＬ－ＣＨ比值为冠心病的危险因素。     

Low–Density Lipoprotein Apheresis Versus Lipid Lowering Drugs in the Treatment of Severe Hypercholesterolemia: Four Years' Experience

Abstract: Elevated lipoprotein concentrations seem to be linked strongly in a dose dependent manner to an increased incidence of atherosclerosis. A total of 47 patients suffering from severe hyperlipidemia were matched to treatment with LDL apheresis (Baxter, Kaneka, Li–popak; 24 patients, aged 50.2 ±11.5 years), diet, and/or lipid–lowering drugs or with diet and lipid–lowering drugs only (23 patients, aged 48.8 ±11.8 years). After treatment periods of 49.8 ±13.4 months (apheresis group, 2,396 treatment sessions) and 38.6 ± 15.1 months (drug group), the ensuing results revealed significant differences (p <0.0001): –47.3% versus –12.1% for total cholesterol, –46.9% versus –21.8% for LDL, +8.4% versus +0.9% for HDL, –52.0% versus – 13.1% for the LDL/HDL ratio, –36.4% versus –16.2% for triglycerides, and –25.9% versus + 1.5% for lipoprotein (a). In the apheresis group, one patient died of myocardial infarction; in the drug group, there was one nonfatal myocardial infarction and the manifestation of coronary heart disease in 3 cases. There were no severe side effects in either group. All patients in the apheresis group responded to therapy. The present trial suggests that a continuing reduction in serum lipid concentrations may lower, in a dose dependent manner, the risk for development and progression of coronary heart disease. Regarding clinical and laboratory results, LDL apheresis seems to be safe, effective therapy for treatment of severe hyperlipidemia.     

Reduced progression of atherosclerosis in apolipoprotein E-deficient mice treated with lacidipine is associated with a decreased susceptibility of low-density lipoprotein to oxidation

A study has been carried out in the apolipoprotein (apo) E-deficient mouse to investigate the activity of lacidipine (a calcium antagonist with antioxidant properties) in inhibiting the development of atherosclerotic lesions; of particular interest were changes in the susceptibility of low-density lipoproteins (LDL) to oxidation. Mice receiving a Western-type diet to accelerate the development of atherosclerosis were treated orally with vehicle or lacidipine at 3 or 10 mg/kg/day for 8 weeks. Lacidipine treatment (at 3 or 10 mg/kg) had no effect on the plasma lipid profile. However, a significant (P < 0.01) dose-related reduction of 43 and 50% of the aortic lesion area in respect to vehicle-treated mice was observed. Moreover, the resistance of mouse plasma LDL to undergo lipid peroxidation was significantly (P < 0.01) increased in apo E-deficient mice treated with lacidipine. The native LDL-like particle, derived from apo E-deficient mice treated with lacidipine, contained significantly lower concentrations of malonyldialdehyde than the vehicle-treated control group (P < 0.01). After exposure to human umbilical vein endothelial cells, LDL-like particle vitamin E levels (expressed as area under the curve; AUC), were significantly higher (P < 0.01) in both the 3 and 10 mg/kg lacidipine-treated groups, in comparison with the vehicle-treated control animals. We conclude that lacidipine reduced the extent of the atherosclerotic area in hypercholesterolaemic apo E-deficient mice, and that this reduction may be associated with the capacity of the drug to decrease the susceptibility of LDL to oxidation.     

Abnormal low density lipoproteins in children with familial hypercholesterolemia — Effet of polyanion exchange resins

Summary In 20 children and adolescents with familial Type IIa hyperlipoproteinemia, serum lipids and lipoproteins were examined before and during treatment with polyanion exchange resins. The composition of LDL was compared to that of healthy siblings. The patients were given Colestyramine (0.6 g/kg body weight) and Colestipol (0.5 g/kg body weight) in a cross-over study for 8 weeks each, after they had been under dietary treatment for at least 12 months. In 6 children, drug treatment had to be stopped due to side-effects. The most common complaints were gastrointestinal discomfort and constipation.Cholesterol, triglycerides and phopholipids were measured in whole serum and cholesterol, triglycerides and Apolipoprotein-B in isolated lipoprotein fractions after ultracentrifugation. Apo-B was determined by radial immunodiffusion.The Apo-B: cholesterol ratio in whole serum and in the LDL fraction was identical in the patients and in the controls. The LDL triglyceride: Apo-B ratio, however, was about 50% lower in the patients. This abnormal LDL composition was not altered by therapy with polyanion exchange resins. HDL cholesterol levels were significantly lower in the patients than in healthy children, and remained low during therapy.The decrease of total and LDL cholesterol (25%) and Apo-B (20%) was similar under both Colestipol and Colestyramine. Triglycerides and phospholipids showed no significant changes in therapy.These studies were supported by grants of the Schweizerische Nationalfonds and the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich 90, Cardiovasculäres System)     

氧化修饰低密度脂蛋白可诱导人单核细胞源树突状细胞形成泡沫细胞

目的： 探讨氧化修饰低密度脂蛋白（ox-LDL）对人单核细胞源树突状细胞（DC）功能的影响。 方法： 采用免疫磁珠法分离人外周血CD14+单核细胞，经含rhGM-CSF（100 μg/L）和rhIL-4（20 μg/L）的Cellgro培养，使其分化为DC。DC与100 mg/L天然的或氧化修饰的LDL孵育72 h后，采用透射电镜和尼罗红染色观察细胞内脂质沉积，流式细胞术检测DC表型（CD1a，CD40，CD86，HLA-DR），混合T淋巴细胞反应检测DC对淋巴细胞增殖的影响，FITC-dextran检测DC吞噬功能，ELISA检测细胞培养上清Th1/Th2 (IL-12/IL-2)细胞因子的浓度。 结果： ox-LDL可诱导DC形成泡沫细胞，而天然的LDL无此作用。经ox-LDL处理的DC吞噬作用明显弱于天然的LDL，而对T细胞增殖作用却明显强于天然的LDL；可明显上调CD80(72.4±9.6 vs 89.5±10.1, P<0.01), CD86(67.2±8.8 vs 80.2±11.6, P＜0.01), HLA-DR(80.6±9.8 vs 86.6±10.8, P<0.01) 和CD1a(40.2±10.3 vs 60.2±9.3, P<0.01)的表达，明显促进DC细胞因子IL-12［(44.3±8.9)ng/L vs (65.1±10.4)ng/L, P<0.05］的分泌，但却降低IL-2［(43.6±7.8）ng/L vs （10.0±4.5）ng/L, P<0.01］。 结论： DC可通过摄取ox-LDL形成泡沫细胞，而后者与成熟DC的功能相似，说明DC可能是泡沫细胞新的来源，在动脉粥样硬化免疫病理发生中具有重要的作用。     

云芝多糖B抑制ox-LDL诱导巨噬细胞株单核细胞趋化蛋白-1mRNA表达的调控机制

目的：探讨云芝多糖（CVPS）-CVPS-B对氧化修饰低密度脂蛋白（ox-LDL）诱导的巨噬细胞(RAW264.7)单核细胞趋化蛋白-1（MCP-1）mRNA表达的影响，及对核因子-κB（NF-κB）和细胞内谷胱甘肽（GSH）的调控作用。方法:应用反转录聚合酶链反应（RT-PCR）测定RAW264.7细胞MCP-1 mRNA的表达；凝胶滞留法（EMSA）测定NF-κB的结合活性；荧光分光光度法测定细胞内GSH的活性。结果:CVPS-B呈剂量依赖性抑制ox-LDL诱导的RAW264.7细胞MCP-1 mRNA的表达。应用GSH 特异性消耗剂buthionine-［S，R］-sulfoximine （BSO），ox-LDL不能诱导RAW264.7细胞MCP-1 mRNA的表达。CVPS-B抑制ox-LDL诱导RAW264.7细胞内GSH活性下降。CVPS-B呈剂量依赖性抑制 ox-LDL诱导的RAW264.7细胞NF-κB活性；在完全消耗GSH的RAW264.7细胞，ox-LDL不能诱导NF-κB的活性。结论:CVPS-B可抑制ox-LDL诱导RAW264.7细胞MCP-1 mRNA的表达；其抑制作用可能通过GSH/NF-κB的调控。